An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials
An adaptive gBOIN design with shrinkage boundaries for phase I dose-finding trials
Abstract Background With the emergence of molecularly targeted agents and immunotherapies, the landscape of phase I trials in oncology has been changed. Though these new therapeutic agents are very likely induce multiple low- or moderate-grade toxicities instead of DLT, most of the existing phase I trial designs account for the …